- Home
- RBOT vs BTAI Comparison
RBOT vs BTAI Comparison
Compare RBOT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | BTAI |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 36.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RBOT | BTAI |
|---|---|---|
| Price | $2.03 | $1.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $26.67 |
| AVG Volume (30 Days) | 62.8K | ★ 301.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.71 | $1.17 |
| 52 Week High | $13.75 | $8.08 |
Technical Indicators
Market Signals| Indicator | RBOT | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 49.74 |
| Support Level | $1.76 | $1.50 |
| Resistance Level | $2.41 | $1.72 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 40.78 | 49.06 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.